Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer

Cancer

Volumn 119, Issue 9, 2013, Pages 1729-1735

  Gray, Phillip J ^a   Paly, Jonathan J ^b   Yeap, Beow Y ^b   Sanda, Martin G ^c   Sandler, Howard M ^d   Michalski, Jeff M ^e   Talcott, James A ^f   Coen, John J ^g   Hamstra, Daniel A ^h   Shipley, William U ^b   Hahn, Stephen M ⁱ   Zietman, Anthony L ^b   Bekelman, Justin E ⁱ   Efstathiou, Jason A ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Continuum Cancer Care Consortium ^*  (United States)

^g Hartford Radiation Oncology Associates   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

3 dimensional conformal radiotherapy; intensity modulated radiotherapy; patient reported outcomes; prostate cancer; proton therapy; quality of life

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER IRRITATION; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; VALIDATION STUDY;

AGED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PROTONS; QUALITY OF LIFE; RADIOTHERAPY;

EID: 84876691403     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27956     Document Type: Article

References (45)

1. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010; 28: 1106-1111.
2. Coen JJ, Bae K, Zietman AL, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011; 81: 1005-1009.
3. Bekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e325-e334.
4. Dinan MA, Robinson TJ, Zagar TM, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012; 82: e781-e786.
5. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
6. Efstathiou JA, Trofimov AV, Zietman AL,. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009; 15: 312-318.
7. Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol. 2011; 60: 908-916.
8. Konski A, Speier W, Hanlon A, Beck JR, Pollack A,. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007; 25: 3603-3608.
9. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307: 1611-1620.
10. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T,. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007; 83: 110-122.
11. Moya del Pina B,. Proton therapy for cancer: a new technology brief. Available at: http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2009/ 090809/page8. [Accessed November 1, 2012 ].
12. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL,. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 148: 435-448.
13. Clark JA, Talcott JA,. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001; 39: 1118-1130.
14. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG,. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56: 899-905.
15. Coen JJ, Paly JJ, Niemierko A, et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: e201-e209.
16. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
17. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003; 21: 3979-3986.
18. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582-592.
19. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011; 117: 1429-1437.
20. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 421-432.
21. Hoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer. 2012; 118: 4619-4626.
22. Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL,. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 2012; 82: 235-241.
23. Pinkawa M, Piroth MD, Fischedick K, et al. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer-predictive factors on irritative symptoms, incontinence and rectal bleeding [serial online]. Radiat Oncol. 2009; 4: 36.
24. Sandler HM, Liu PY, Dunn RL, Khan DC, Tropper SE, Sanda MG, et al. Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010; 75: 1004-1008.
25. Michalski JM, Yan Y, Watkins-Bruner D, et al. Preliminary analysis of 3D-CRT vs IMRT on the high dose arm of the RTOG 0126 Prostate Cancer Trial: toxicity report. Int J Radiat Oncol Biol Phys. 2011; 81: S1-S2.
26. Watkins Bruner D, Hunt D, et al. Preliminary analysis of 3D-CRT vs IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: patient reported outcomes. J Radiat Oncol Biol Phys. 2011; 81: S44-S44.
27. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010; 76 (3 suppl): S10-S19.
28. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO,. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010; 76 (3 suppl): S123-S129.
29. Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007; 69: 444-453.
30. Schwarz M, Pierelli A, Fiorino C, et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison. Radiother Oncol. 2011; 98: 74-80.
31. Dias RS, Giordani AJ, Souhami L, Segreto RA, Segreto HR,. Rectal planning risk volume correlation with acute and late toxicity in 3-dimensional conformal radiation therapy for prostate cancer. Technol Cancer Res Treat. 2011; 10: 585-590.
32. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008; 71: 1065-1073.
33. Vavassori V, Fiorino C, Rancati T, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007; 67: 1401-1410.
34. Rancati T, Fiorino C, Fellin G, et al. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiother Oncol. 2011; 100: 124-130.
35. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000; 47: 103-113.
36. Karlsdottir A, Muren LP, Wentzel-Larsen T, Dahl O,. Late gastrointestinal morbidity after 3-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys. 2008; 70: 1478-1486.
37. Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 2001; 49: 685-698.
38. Nguyen PL, Chen RC, Hoffman KE, et al. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010; 78: 1081-1085.
39. Tucker SL, Dong L, Michalski JM, et al. Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from Radiation Therapy Oncology Group protocol 94-06. Int J Radiat Oncol Biol Phys. 2012; 84: 390-395.
40. Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 2008; 70: 1130-1137.
41. Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013; 105: 25-32.
42. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB,. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002; 40 (8 suppl): IV-62-IV-68.
43. Muanza TM, Albert PS, Smith S, et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2005; 62: 1316-1321.
44. Hovdenak N, Karlsdottir A, Sorbye H, Dahl O,. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncol. 2003; 42: 741-748.
45. Shah A, Efstathiou JA, Paly JJ, et al. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 83: e19-e19.